Skye Bioscience Inc (SKYE) Stock Analysis
Verdict: AVOID
Pre-revenue biotech facing a terminal liquidity crunch; unless a major trial success or capital raise occurs, insolvency risk is imminent.
Investment score: 32/100
Analysis as of
Is Skye Bioscience Inc stock worth reviewing? The TradeMates thesis
SKYE is a micro-cap biotech with a broken chart and a severe cash burn that far exceeds current liquidity.
7-factor investment score
- Valuation: 15/100 (weight 20%)
- Financial Health: 10/100 (weight 15%)
- Technical Momentum: 20/100 (weight 15%)
- Earnings Quality: 25/100 (weight 15%)
- Insider Sentiment: 50/100 (weight 10%)
- Analyst Consensus: 60/100 (weight 10%)
- Risk-Adjusted Return: 25/100 (weight 15%)
Skye Bioscience Inc opportunities and risks
What speaks for SKYE
- Obesity Market Tailwinds
What speaks against SKYE
- Imminent Liquidity Rupture
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| SKYE | n/a | 0.0x | n/a | 0.0% | 0.0% | -198.5% |
| MRKR | n/a | 7.5x | n/a | -347.2% | -520.3% | -50.6% |
| ATOS | n/a | 0.0x | 0.3x | 0.0% | 0.0% | -168.3% |
| CELU | n/a | 0.7x | n/a | 76.0% | -345.4% | -69.6% |
| TVGN | n/a | 0.0x | n/a | 0.0% | 0.0% | -53.7% |
| CLRB | n/a | 0.0x | n/a | 0.0% | 0.0% | -219.8% |
| Peer median | n/a | 0.0x | n/a | 0.0% | 0.0% | -69.6% |
Frequently asked questions about Skye Bioscience Inc (SKYE)
Is SKYE stock a good investment?
The TradeMates model rates Skye Bioscience Inc as AVOID with an investment score of 32/100. SKYE is a micro-cap biotech with a broken chart and a severe cash burn that far exceeds current liquidity. This is algorithmic model output, not personal investment advice.
Is SKYE stock a buy?
The TradeMates model verdict for SKYE is AVOID with an investment score of 32/100. Treat this as a model signal to review, not a personal buy recommendation.